Indeed, reducing germline Myc by 50% prolonged survival across the full spectrum of tumor types in mice lacking Trp53, indicating that Myc acts downstream of, or in parallel with, any cell-type specific oncogenic pathways. This evidence concerns the gene MYC and neoplasm.